1. Home
  2. GSIW vs SCYX Comparison

GSIW vs SCYX Comparison

Compare GSIW & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSIW
  • SCYX
  • Stock Information
  • Founded
  • GSIW 2016
  • SCYX 1999
  • Country
  • GSIW Hong Kong
  • SCYX United States
  • Employees
  • GSIW N/A
  • SCYX N/A
  • Industry
  • GSIW
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • GSIW
  • SCYX Health Care
  • Exchange
  • GSIW Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • GSIW 27.2M
  • SCYX 28.5M
  • IPO Year
  • GSIW 2023
  • SCYX 2014
  • Fundamental
  • Price
  • GSIW $1.75
  • SCYX $0.74
  • Analyst Decision
  • GSIW
  • SCYX
  • Analyst Count
  • GSIW 0
  • SCYX 0
  • Target Price
  • GSIW N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • GSIW 2.6M
  • SCYX 188.8K
  • Earning Date
  • GSIW 01-01-0001
  • SCYX 08-07-2025
  • Dividend Yield
  • GSIW N/A
  • SCYX N/A
  • EPS Growth
  • GSIW N/A
  • SCYX N/A
  • EPS
  • GSIW N/A
  • SCYX N/A
  • Revenue
  • GSIW $1,313,795.00
  • SCYX $2,630,000.00
  • Revenue This Year
  • GSIW N/A
  • SCYX $410.22
  • Revenue Next Year
  • GSIW N/A
  • SCYX $248.83
  • P/E Ratio
  • GSIW N/A
  • SCYX N/A
  • Revenue Growth
  • GSIW N/A
  • SCYX N/A
  • 52 Week Low
  • GSIW $0.35
  • SCYX $0.66
  • 52 Week High
  • GSIW $12.30
  • SCYX $2.28
  • Technical
  • Relative Strength Index (RSI)
  • GSIW 72.13
  • SCYX 46.93
  • Support Level
  • GSIW $1.26
  • SCYX $0.67
  • Resistance Level
  • GSIW $1.66
  • SCYX $0.83
  • Average True Range (ATR)
  • GSIW 0.14
  • SCYX 0.05
  • MACD
  • GSIW -0.02
  • SCYX 0.01
  • Stochastic Oscillator
  • GSIW 92.25
  • SCYX 47.06

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: